1. Objectifs

Intentions :
«The aims of this study are to (1) confirm [the authors’] long-term recruitment capacity for future follow-up and (2) determine the spectrum of neurodevelopmental outcomes at preschool age following neonatal DHA [docosahexaenoic acid] supplementation in children born very preterm.» (p. 2)

2. Méthode

Échantillon/Matériau :
«Children of mothers enrolled in the MOBYDIck trial in any of the five sites from the province of Quebec (CHU de Québec-Université Laval, CHU de Sherbrooke, CHU Sainte-Justine, Jewish General Hospital and McGill University Health Centre) will be eligible for this study when they are 5 years’ CA [corrected age] (range from 57 to 66 months’ CA).» (p. 3)

Instruments :
- Guide d’entretien semi-directif
- Questionnaires

Type de traitement des données :
Analyse de contenu
Analyse statistique

3. Résumé

«This follow-up study in a subset of participants of the MOBYDIck trial will help determine the impact of maternal DHA supplementation during the neonatal period on brain development and neurodevelopmental outcomes of breastfed very preterm infants. As such, this follow-up at preschool age is part of a longer term longitudinal cohort study, which will include brain imaging with MRI and neurodevelopmental assessment at 8 years of age. This proposed longitudinal follow-up study is unique and will contribute to better understand the role of DHA supplementation during the neonatal period on brain development and the neurodevelopmental trajectory of high-risk preterm infants. This follow-up study at preschool age will inform the development of the longer term follow-up planned at school age by establishing our long-term recruitment capacity, quantifying the acceptability and addressing parents’ views and concerns early in the process. This study will also contribute to better identify the characteristics of participants lost to follow-up.» (p. 7)